Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03333655 · ClinicalTrials.gov registry record · Phase 4
Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT03333655 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 15 participants.
The verdict
NCT03333655, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.
Interventions
- PROCEDURE Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-02-16 |
| Est. Completion | 2022-08-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03333655
The ClinicalTrials.gov registry entry for NCT03333655 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biopsy is the first listed.
NCT03333655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03333655 about?
NCT03333655 is a clinical study titled "Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy". The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.
What is the current status of trial NCT03333655?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2018-02-16. Estimated completion is 2022-08-04.
What interventions are being tested in trial NCT03333655?
The interventions under investigation include: Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03333655?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.